Embracing Time and Hope: A Journey Towards Renewal and Resilience
A Personal Journey Through Pancreatic Cancer: Michael Francis’ Story
Michael Francis, a unique rose farmer from the U.S., has faced the formidable challenge of pancreatic adenocarcinoma, commonly known as pancreatic cancer. His battle began on November 26, 2018, when a severe case of jaundice prompted him to seek medical attention. This decision, influenced by his supportive wife, led to a life-altering diagnosis at the Mayo Clinic Hospital in Phoenix, Arizona.
The Diagnosis and Initial Steps
After just six hours of being evaluated by his doctor, Michael found himself undergoing a CT scan that revealed a mass in his pancreas, indicating stage III pancreatic cancer. Following this shocking news, a stent was placed in his bile duct, alleviating the jaundice almost immediately.
- Key diagnosis date: November 26, 2018
- Institution: Mayo Clinic Hospital, Phoenix
- Diagnosis: Stage III pancreatic cancer
Exploring Treatment Options
Upon consulting with an oncologist, Michael learned that surgery wasn’t an option due to the tumor’s proximity to vital blood vessels. The recommended treatment plan consisted of chemotherapy using gemcitabine and Abraxane. Faced with a median life expectancy of three years, Michael and his family sought alternative options.
Through a friend’s suggestion, he connected with TGen in Phoenix, known for its extensive pancreatic cancer research. This led to an appointment with Dr. Michael Gordon at the Virginia G. Piper Cancer Center in Scottsdale. Dr. Gordon’s encouraging words, “I think we can do better than three years,” sparked hope for Michael and his family.
Participating in a Clinical Trial
In December, Michael met with nurse practitioner Gayle Jameson and enrolled in a phase II clinical trial named NABPLAGEM. Under the guidance of Dr. Erkut Borazanci, he underwent six cycles of chemotherapy, combining gemcitabine, nab-paclitaxel, and cisplatin until April 2019.
Following chemotherapy, he received capecitabine and intensity-modulated radiation therapy (IMRT) from Dr. Steven Sckolnik, wrapping up his treatment in June 2019.
- Trial name: NABPLAGEM
- Chemotherapy agents: Gemcitabine, nab-paclitaxel, cisplatin
- End of initial treatment: June 17, 2019
Current Health Status and Ongoing Monitoring
Michael remains under the watchful eye of Dr. Borazanci, with CA 19-9 tests and scans every two months. His most recent CA 19-9 level was 66, and scans have shown that the tumor is stable with no signs of metastasis. He continues to take capecitabine as a maintenance therapy along with vitamin D and metformin, despite not having diabetes.
- Latest CA 19-9 level: 66
- Monitoring frequency: Every two months
- Current treatment: Capecitabine
Michael expresses immense gratitude for the dedicated nursing staff at Virginia Piper Cancer Center, including Gayle, Paula, Ashley, Dana, Mary, and especially Dr. Borazanci.
Looking Forward with Hope
Thanks to the groundbreaking clinical trial, Michael is not only alive but also managing a limited work schedule, enjoying golf with his wife, and cherishing moments with his grandchildren. His story embodies a message of resilience, underscoring the importance of time and hope in the fight against pancreatic cancer.
For those seeking information on clinical trials, visit Learn more about finding clinical trials.
Michael’s experience highlights the critical role of clinical trials and personalized care in navigating the challenges of pancreatic cancer, offering inspiration and hope to many facing similar battles.
